Barinthus Biotherapeutics PLC
BRNS
查看详细走势图
0.739USD
+0.008+1.04%
收盘 12/19, 16:00（美东）报价延迟15分钟
30.17M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.04%
5天
+8.79%
1月
+6.12%
6月
-12.14%
今年开始到现在
-38.82%
1年
-33.42%
查看详细走势图
TradingKey Barinthus Biotherapeutics PLC股票评分
单位: USD 更新时间: 2025-12-19操作建议
Barinthus Biotherapeutics PLC当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名129/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.50。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Barinthus Biotherapeutics PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
5.500
目标均价
+682.58%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Barinthus Biotherapeutics PLC亮点
亮点风险
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
业绩增长期
公司处于发展阶段，最新年度总收入14.97M美元
估值高估
公司最新PE估值-0.39，处于3年历史高位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值66.30K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.89
Barinthus Biotherapeutics PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Barinthus Biotherapeutics PLC简介
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
公司代码BRNS
公司Barinthus Biotherapeutics PLC
CEOEnright (William J)
网址https://www.barinthusbio.com/
常见问题
Barinthus Biotherapeutics PLC(BRNS)的当前股价是多少？
Barinthus Biotherapeutics PLC(BRNS)的当前股价是 0.739。
Barinthus Biotherapeutics PLC的股票代码是什么？
Barinthus Biotherapeutics PLC的股票代码是BRNS。
Barinthus Biotherapeutics PLC股票的52周最高点是多少？
Barinthus Biotherapeutics PLC股票的52周最高点是2.920。
Barinthus Biotherapeutics PLC股票的52周最低点是多少？
Barinthus Biotherapeutics PLC股票的52周最低点是0.640。
Barinthus Biotherapeutics PLC的市值是多少？
Barinthus Biotherapeutics PLC的市值是30.17M。
Barinthus Biotherapeutics PLC的净利润是多少？
Barinthus Biotherapeutics PLC的净利润为-61.07M。
现在Barinthus Biotherapeutics PLC(BRNS)的股票是买入、持有还是卖出？
根据分析师评级，Barinthus Biotherapeutics PLC(BRNS)的总体评级为买入，目标价格为5.500。
Barinthus Biotherapeutics PLC(BRNS)股票的每股收益（EPS TTM）是多少
Barinthus Biotherapeutics PLC(BRNS)股票的每股收益（EPS TTM）是-1.884。
相关品种
